613 related articles for article (PubMed ID: 31661001)
1. Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1.
D'Alterio C; Buoncervello M; Ieranò C; Napolitano M; Portella L; Rea G; Barbieri A; Luciano A; Scognamiglio G; Tatangelo F; Anniciello AM; Monaco M; Cavalcanti E; Maiolino P; Romagnoli G; Arra C; Botti G; Gabriele L; Scala S
J Exp Clin Cancer Res; 2019 Oct; 38(1):432. PubMed ID: 31661001
[TBL] [Abstract][Full Text] [Related]
2. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
3. A novel CXCR4-targeted near-infrared (NIR) fluorescent probe (Peptide R-NIR750) specifically detects CXCR4 expressing tumors.
Santagata S; Portella L; Napolitano M; Greco A; D'Alterio C; Barone MV; Luciano A; Gramanzini M; Auletta L; Arra C; Zannetti A; Scala S
Sci Rep; 2017 May; 7(1):2554. PubMed ID: 28566721
[TBL] [Abstract][Full Text] [Related]
4. In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies.
Ieranò C; Righelli D; D'Alterio C; Napolitano M; Portella L; Rea G; Auletta F; Santagata S; Trotta AM; Guardascione G; Liotti F; Prevete N; Maiolino P; Luciano A; Barbieri A; Di Mauro A; Roma C; Esposito Abate R; Tatangelo F; Pacelli R; Normanno N; Melillo RM; Scala S
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246475
[TBL] [Abstract][Full Text] [Related]
5. CXCL12 loaded-dermal filler captures CXCR4 expressing melanoma circulating tumor cells.
Ieranò C; D'Alterio C; Giarra S; Napolitano M; Rea G; Portella L; Santagata A; Trotta AM; Barbieri A; Campani V; Luciano A; Arra C; Anniciello AM; Botti G; Mayol L; De Rosa G; Pacelli R; Scala S
Cell Death Dis; 2019 Jul; 10(8):562. PubMed ID: 31332163
[TBL] [Abstract][Full Text] [Related]
6. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.
Zeng Y; Li B; Liang Y; Reeves PM; Qu X; Ran C; Liu Q; Callahan MV; Sluder AE; Gelfand JA; Chen H; Poznansky MC
FASEB J; 2019 May; 33(5):6596-6608. PubMed ID: 30802149
[TBL] [Abstract][Full Text] [Related]
7. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M
J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777
[TBL] [Abstract][Full Text] [Related]
8. Salvia mitiorrhiza Bunge aqueous extract attenuates infiltration of tumor-associated macrophages and potentiates anti-PD-L1 immunotherapy in colorectal cancer through modulating Cox2/PGE2 cascade.
Song M; Qian C; Zhang T; Tang Y; Zhou Y; Wei Z; Wang A; Zhong C; Zhao Y; Lu Y
J Ethnopharmacol; 2023 Nov; 316():116735. PubMed ID: 37286115
[TBL] [Abstract][Full Text] [Related]
9. Combination of PD-1 Checkpoint Blockade and Botulinum Toxin Type A1 Improves Antitumor Responses in Mouse Tumor Models of Melanoma and Colon Carcinoma.
Kwak S; Lee JY; Kim MJ; Lee HJ; Lee DK; Kang J; Kang WH; Son WC; Cruz DJM
Immunol Invest; 2023 Nov; 52(6):749-766. PubMed ID: 37403798
[TBL] [Abstract][Full Text] [Related]
10. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
11. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA
Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064
[TBL] [Abstract][Full Text] [Related]
12. New CXCR4 Antagonist Peptide R (Pep R) Improves Standard Therapy in Colorectal Cancer.
D'Alterio C; Zannetti A; Trotta AM; Ieranò C; Napolitano M; Rea G; Greco A; Maiolino P; Albanese S; Scognamiglio G; Tatangelo F; Tafuto S; Portella L; Santagata S; Nasti G; Ottaiano A; Pacelli R; Delrio P; Botti G; Scala S
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708431
[TBL] [Abstract][Full Text] [Related]
13. Pingyangmycin enhances the antitumor efficacy of anti-PD-1 therapy associated with tumor-infiltrating CD8
Shan CK; Du YB; Zhai XT; Wang YX; Li Y; Gong JH; Ge ZJ; Liu XJ; Zhen YS
Cancer Chemother Pharmacol; 2021 Mar; 87(3):425-436. PubMed ID: 33388950
[TBL] [Abstract][Full Text] [Related]
14. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model.
Mercurio L; Ajmone-Cat MA; Cecchetti S; Ricci A; Bozzuto G; Molinari A; Manni I; Pollo B; Scala S; Carpinelli G; Minghetti L
J Exp Clin Cancer Res; 2016 Mar; 35():55. PubMed ID: 27015814
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.
Knudson KM; Hicks KC; Alter S; Schlom J; Gameiro SR
J Immunother Cancer; 2019 Mar; 7(1):82. PubMed ID: 30898149
[TBL] [Abstract][Full Text] [Related]
16. Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature.
Sabbatino F; Marra A; Liguori L; Scognamiglio G; Fusciello C; Botti G; Ferrone S; Pepe S
J Immunother Cancer; 2018 Nov; 6(1):126. PubMed ID: 30458852
[TBL] [Abstract][Full Text] [Related]
17. Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases.
Portella L; Vitale R; De Luca S; D'Alterio C; Ieranò C; Napolitano M; Riccio A; Polimeno MN; Monfregola L; Barbieri A; Luciano A; Ciarmiello A; Arra C; Castello G; Amodeo P; Scala S
PLoS One; 2013; 8(9):e74548. PubMed ID: 24058588
[TBL] [Abstract][Full Text] [Related]
18. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.
Remy-Ziller C; Thioudellet C; Hortelano J; Gantzer M; Nourtier V; Claudepierre MC; Sansas B; Préville X; Bendjama K; Quemeneur E; Rittner K
Hum Vaccin Immunother; 2018 Jan; 14(1):140-145. PubMed ID: 28925793
[TBL] [Abstract][Full Text] [Related]
19. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
20. B16 melanoma control by anti-PD-L1 requires CD8+ T cells and NK cells: application of anti-PD-L1 Abs and Trp2 peptide vaccines.
Ji S; Lee J; Lee ES; Kim DH; Sin JI
Hum Vaccin Immunother; 2021 Jul; 17(7):1910-1922. PubMed ID: 33522416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
